Abstract
Objective
This study sought to determine if targeted drug screening of newborns was effective in identifying a positive drug test result.
Study design
This was a retrospective cross-sectional study. A total of 340 infants met criteria for drug screening. Sensitivity and specificity were used to evaluate each of the potential risk factors in terms of their ability to predict a positive drug test result. Two-sample t-tests were used to compare differences in Finnegan scores between babies with a positive drug test result and those with a negative one.
Result
The risk factor with the highest sensitivity was maternal history of drug use. The difference in the Finnegan scores between groups was statistically significant.
Conclusion
The risk factors associated with this study were not very sensitive. The only way to identify all infants at risk of NAS is to standardize the screening process and apply to all infants.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
References
HCUP fast stats – neonatal abstinence syndrome (NAS) among newborn hospitalizations. Healthcare Cost and Utilization Project (HCUP). Updated 9/8/2021. Accessed 10/4/2021. https://www.hcup-us.ahrq.gov/faststats/NASServlet?setting1=IP&location=US
Winkelman TNA, Villapiano N, Kozhimannil KB, Davis MM, Patrick SW. Incidence and costs of neonatal abstinence syndrome among infants with Medicaid: 2004-2014. Pediatrics 2018;141:1–10. https://doi.org/10.1542/peds.2017-3520
The American College of Obstetricians and Gynecologists (ACOG. Committee opinion number 711: Opioid use and opioid use disorder in pregnancy. Obstet Gynecol. 2017;130:e81–e94. https://doi.org/10.1097/AOG.0000000000002235
McQueen K, Murphy-Oikonen J. Neonatal abstinence Syndrome. N. Engl J Med. 2016;375:2468–79. https://doi.org/10.1056/NEJMra1600879
Timpson W, Killoran C, Maranda L, Picarillo A, Bloch-Salisbury E. A quality improvement initiative to increase scoring consistency and accuracy of the Finnegan tool. Adv Neonatal Care. 2018;18:70–8. https://doi.org/10.1097/ANC.0000000000000441
Maguire DJ, Taylor S, Armstrong K, Shaffer-Hudkins E, Germain AM, Brooke SS, et al. Long-term outcomes of infants with neonatal abstinence syndrome. Neonatal Netw. 2016;35:277–86. https://doi.org/10.1891/0730-0832.35.5.277
Terplan M, Minkoff H. Neonatal abstinence syndrome and ethical approaches to the identification of pregnant women who use drugs. Obstet Gynecol. 2017;129:164–7. https://doi.org/10.1097/AOG.0000000000001781
Price HR, Collier AC, Wright TE. Screening pregnant women and their neonates for illicit drug use: consideration of the integrated technical, medical, ethical, legal, and social issues. Front Pharmacol. 2018;9:1–11. https://doi.org/10.3389/fphar.2018.00961
Umbilical cord tissue drug testing. United Stated Drug Testing Laboratories, Inc (USDTL). https://www.usdtl.com/testing/umbilical-cord-tissue-drug-test-labs. Published 2022. Accessed 02/20/2022.
Jones J. Why is confirmation testing necessary? NeoTox. 2017;8:5–7. https://issuu.com/usdtl/docs/neotox_v8i1_2017_for_web/4
Bogen DL, Whalen BL, Kair LR, Vining M, King BA. Wide variation found in care of opioid-exposed newborns. Acad Pediatr. 2017;17:374–80. https://doi.org/10.1016/j.acap.2016.10.003
Miller C, Lanham A, Welsh C, Ramanadhan S, Terplan M. Screening, testing, and reporting for drug and alcohol use on labor and delivery: a survey of Maryland birthing hospitals. Soc Work Health Care. 2014;53:659–69. https://doi.org/10.1080/00981389.2014.916375
Wood KE, Sinclair LL, Rysgaard CD, Strathmann FG, McMillin GA, Krasowski MD. Retrospective analysis of the diagnostic yield of newborn drug testing. BMC Preg Childbirth. 2014;14:1–9. https://doi.org/10.1186/1471-2393-14-250
Buchi KF, Suarez C, Varner MW. The prevalence of prenatal opioid and other drug use in Utah. Am J Perinatol. 2013;30:241–4. https://doi.org/10.1055/s-0032-1323586
Colby JM. Comparison of umbilical cord tissue and meconium for the confirmation of in utero drug exposure. Clin Biochem. 2017;50:784–90. https://doi.org/10.1016/j.clinbiochem.2017.03.006
Ellsworth MA, Stevens TP, D’Angio CT. Infant race affects application of clinical guidelines when screening for drugs of abuse in newborns. Pediatrics 2010;125:e1379–e1385. https://doi.org/10.1542/peds.2008-3525
Murphy-Oikonen J, Montelpare W, Southon S, Bertoldo L, Persichino N. Identifying infants at risk for neonatal abstinence syndrome: a retrospective cohort comparison study of 3 screening approaches. J Perinat Neonatal Nurs. 2010;24:366–72. https://doi.org/10.1097/JPN.0b013e3181fa13ea
Son SL, Guiahi M, Heyborne KD. Historical and clinical factors associated with positive urine toxicology screening on labor and delivery. Eur J Obstet Gynecol Reprod Biol. 2018;228:261–6. https://doi.org/10.1016/j.ejogrb.2018.07.020
Wexelblatt SL, Ward LP, Torok K, Tisdale E, Meinzen-Derr JK, Greenberg JM. Universal maternal drug testing in a high-prevalence region of prescription opiate abuse. J Pediatrics. 2015;166:582–6. https://doi.org/10.1016/j.jpeds.2014.10.004
Wood KE, Smith P, Krasowski MD. Newborn drug testing practice in Iowa birthing hospitals. J Neonatal-Perinat Med. 2017;10:445–50. https://doi.org/10.3233/NPM-16153
Kreshak A, Villano J, Clark A, Deak P, Clark R, Miller C. A descriptive regional study of drug and alcohol use in pregnant women using results from urine drug testing by liquid chromatography-tandem mass spectrometry. Am J Drug Alcohol Abus. 2016;42:178–86. https://doi.org/10.3109/00952990.2015.1116540
Schauberger CW, Newbury EJ, Colburn JM, Al-Hamadani M. Prevalence of illicit drug use in pregnant women in a Wisconsin private practice setting. Am J Obstet Gynecol 2014;211:255.e1–4. https://doi.org/10.1016/j.ajog.2014.03.023
Lange S, Shield K, Koren G, Rehm J, Popova S. A comparison of the prevalence of prenatal alcohol exposure obtained via maternal self-reports versus meconium testing: a systemic literature review and meta-analysis. BMC Pregnancy Childbirth. 2014;14:1–11. https://doi.org/10.1186/1471-2393-14-127
Montgomery DP, Plate CA, Jones M, Jones J, Rios R, Lambert DK, et al. Using umbilical cord tissue to detect fetal exposure to illicit drugs: a multicentered study in Utah and New Jersey. J Perinatol. 2008;28:750–3. https://doi.org/10.1038/jp.2008.97
Palmer KL, Wood KE, Krasowski MD. Evaluating a switch from meconium to umbilical cord tissue for newborn drug testing: a retrospective study at an academic medical center. Clin Biochem. 2017;50:255–61. https://doi.org/10.1016/j.clinbiochem.2016.11.026
Pomar EG, Finnegan LP, Devlin L, Bada H, Concina V, Ibonia KT, et al. Simplification of the Finnegan Neonatal Abstinence Scoring System: retrospective study of two institutions in the USA. BMJ Open. 2017;7:1–7. https://doi.org/10.1136/bmjopen-2017-016176
Jhaveri R, Broder T, Bhattacharya D, Peters MG, Kim AY, Jonas MM. Universal screening of pregnant women for Hepatitis C: the time is now. Clin Infect Dis. 2018;67:1493–7. https://doi.org/10.1093/cid/ciy586
Ishikawa N, Dalal S, Johnson C, Hogan DR, Shimbo T, Shaffer N, et al. Should HIV testing for all pregnant women continue? Cost effectiveness of universal antenatal testing compared to focused approaches across high to very low HIV prevalence settings. J Int AIDS Soc. 2016;19:1–9. https://doi.org/10.7448/IAS.19.21212
Frazer Z, McConnell K, Jansson LM. Treatment for substance use disorders in pregnant women: motivators and barriers. Drug Alcohol Depend. 2019;205:1–6. https://doi.org/10.1016/j.drugalcdep.2019.107652
Acknowledgements
I would like to thank Dr. Nicole Garritano, DNP, APRN, CPNP-AC, for her help in reviewing this manuscript and providing editing recommendations as well as providing support and guidance during final revisions.
Author information
Authors and Affiliations
Contributions
AJK was the principal investigator in this study and was responsible for the concept and design of the study, the IRB application, collection of data and statistical analysis, figure and table creation, and was the sole writer of the manuscript and made all revisions in collaboration with the co-authors. MKR provided substantial contributions to the acquisition of data, statistical analysis, and interpretation of data. She also was involved in the revisions to improve intellectual content. LKS provided substantial contributions to the concept and design of this study and the acquisition of data. She also was involved in the revisions to improve intellectual content. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
An IRB application was submitted to the University of Kentucky’s and Baptist Health Lexington’s IRB and both were approved in September 2019, including a waiver of informed consent.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Karr, A.J., Rayens, M.K. & Scott, L.K. Neonatal abstinence syndrome: Effectiveness of targeted umbilical cord drug screening. J Perinatol 42, 1038–1043 (2022). https://doi.org/10.1038/s41372-022-01457-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41372-022-01457-8